Hi stardestr0yer, been a tough road for this one. They only received FDA approval mid last year so realistically were only then able to start a commercial rollout and then hit by Covid. They have some excellent staff who have done it all with Resmed. They have signed a heap of contracts but the revenue does not seem to translate onto the 4c and the cashburn is big.
IMO the OVN presentations cannot be trusted and are well crafted BS in order to raise capital .
If they do happen to gain commercial traction then this company is a winner but at this stage I only hold options which I envisage will never be in a position to be exercised. This is a capital hungry company.
OVN Price at posting:
26.0¢ Sentiment: None Disclosure: Held
